New Delhi: As the trial of the Coronavirus vaccine progresses at a rapid pace, there is an increasing expectation that an approved vaccine will be available in the Indian market by early 2021. Bernstein said this in a report.
Work is rapidly underway on four vaccines
Currently, there are four potential vaccines worldwide, expected to be approved in late 2020 or early 2021. Two of these vaccines have been partnered by ‘AstraZeneca and Oxford’s Viral Vector Vaccine’ and ‘Novavax’s Protein Subunit Vaccine’.
According to the report, “the tests in the first and second phase appear to be reliable for increasing the safety and immune response potential of these two vaccines. We are optimistic that an approved vaccine will hit the market in India in the first quarter of 2021.
Bernstein said the cost of the vaccine could be three to six dollars (Rs 225 to 550) per dose, and it could take up to two years for collective immunity to develop due to implementation issues. The reason for this is the lack of experience in the field of mass vaccination.
Read this too – be careful! Fake messages are being sent to these states in the name of ED, know what’s going on
According to the report, India has two experiences with large-scale vaccination. One was the 2011 Polia Eradication Campaign and the other the recent Intensive Mission Indradhanush (IMI), but their level was one third of the level required for the Kovid-19.
India faces challenges
Bernstein said the number of cold stores and the lack of a skilled workforce are two major challenges. Even assuming that the implementation speed will be twice as fast as before, it will take another 18 to 20 months for the government program to be implemented.
He said: “We believe that vaccines will initially be made available to sensitive departments such as health workers and people over 65, etc. After that, the vaccine can be given to those engaged in essential services and to the economically poor.
According to the report, Novavax’s vaccine gives better results than AstraZeneca and Oxford. Both have delivered good results in the first two phases and are now in the third phase. For this, a person must give two doses with an interval of 21 to 28 days.
India is capable of making a billion doses of vaccine
Bernstein said the Serum Institute of India is all set to be the first to introduce the vaccine. The Serum Institute has partnered with AstraZeneca and both Oxford and Novavax to produce their potential vaccines. It has the ability to produce both a protein subunit and a viral vector vaccine. If necessary, the power of both types can be increased by changing one. We don’t see any hindrance on the manufacturing front.
He said, ‘Serum Institute is also working on an additional capacity of one billion doses. We estimate that they can produce 60 crore doses by 2021 and a billion doses by 2022. Doses of 40 to 50 crore of this will be available for India in 2021.
In addition, three companies from India, Zydus, Bharat Biotech and Biological e are also working on their own vaccines. These vaccines are in phase I and phase II studies.